Cannabis Use Disorder, Moderate Clinical Trial
Official title:
Gender and Sex Hormone Influences on Cannabis Use Disorder Remission
Adults (ages 18+) who would like to reduce their cannabis use (N=224) will be enrolled in an 8-week treatment program. All participants will receive counseling (1 goals session with a therapist followed by 7 weekly computerized cognitive-behavioral therapy sessions). Detailed cannabis assessments (biological and self-report) will be conducted throughout treatment and at 1-, 2-, and 3-months post-treatment completion. Daily electronic diaries will be administered via text message to record detailed logs of cannabis use quantity and frequency. Salivary samples will be collected (and video observed) daily throughout treatment to analyze for progesterone.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04106336 -
Cortical Excitability and Role of rTMS in Cannabis Use Disorder
|
Early Phase 1 | |
| Not yet recruiting |
NCT06225232 -
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
|
Phase 2 | |
| Completed |
NCT04923230 -
Pilot Test of Parent-Focused Cannabis-Related Actions and Practices Intervention for Adolescent Marijuana Abuse
|
N/A | |
| Completed |
NCT04902092 -
Brain Exercise and Addiction Trial
|
N/A | |
| Recruiting |
NCT05064319 -
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT04567394 -
Cannabis Use Disorder Treatment Study
|
Phase 2 |